[
  {
    "ts": null,
    "headline": "Boston Scientific At The Starting Line Again After Its Stock Hits A Record High, Consolidates.",
    "summary": "Boston Scientific shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.",
    "url": "https://finnhub.io/api/news?id=3b3df4d8ead933ab9822e5cd9f6c29f0f22c11b87ca8c436fc4906a7e6b69542",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755030320,
      "headline": "Boston Scientific At The Starting Line Again After Its Stock Hits A Record High, Consolidates.",
      "id": 136323066,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.",
      "url": "https://finnhub.io/api/news?id=3b3df4d8ead933ab9822e5cd9f6c29f0f22c11b87ca8c436fc4906a7e6b69542"
    }
  },
  {
    "ts": null,
    "headline": "SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts",
    "summary": "Surmodics delivers third-quarter fiscal 2025 earnings beat with narrower loss, as revenue tops estimates despite lower SurVeil DCB sales.",
    "url": "https://finnhub.io/api/news?id=bc7c9d9a7440d9d0956206996e2510fd4d4c426c16525ca877e7e9736849a332",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755018120,
      "headline": "SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts",
      "id": 136321135,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Surmodics delivers third-quarter fiscal 2025 earnings beat with narrower loss, as revenue tops estimates despite lower SurVeil DCB sales.",
      "url": "https://finnhub.io/api/news?id=bc7c9d9a7440d9d0956206996e2510fd4d4c426c16525ca877e7e9736849a332"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons Growth Investors Will Love Boston Scientific (BSX)",
    "summary": "Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.",
    "url": "https://finnhub.io/api/news?id=7e319fb6db968b3c6e4e313727710ea29c05782c9a6f0a954e9c3c39906e85d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755017101,
      "headline": "3 Reasons Growth Investors Will Love Boston Scientific (BSX)",
      "id": 136323068,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.",
      "url": "https://finnhub.io/api/news?id=7e319fb6db968b3c6e4e313727710ea29c05782c9a6f0a954e9c3c39906e85d4"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific Stock Hits A Record High, Consolidates. Prepping For Another Run?",
    "summary": "Boston Scientific Stock Hits A Record High, Consolidates. Prepping For Another Run?",
    "url": "https://finnhub.io/api/news?id=f5db7457853389923098c6c23f0522e9a367c2991b6b24588a09bbb9f48db715",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755015920,
      "headline": "Boston Scientific Stock Hits A Record High, Consolidates. Prepping For Another Run?",
      "id": 136332735,
      "image": "",
      "related": "BSX",
      "source": "DowJones",
      "summary": "Boston Scientific Stock Hits A Record High, Consolidates. Prepping For Another Run?",
      "url": "https://finnhub.io/api/news?id=f5db7457853389923098c6c23f0522e9a367c2991b6b24588a09bbb9f48db715"
    }
  },
  {
    "ts": null,
    "headline": "Reasons to Add Veeva Systems Stock to Your Portfolio for Now",
    "summary": "VEEV's strong first quarter, product innovations and strategic deals drive growth prospects despite rising costs.",
    "url": "https://finnhub.io/api/news?id=4513415e80b937a674ba533c72eabee702be6345ccfc1b95da6844046787c23c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755013260,
      "headline": "Reasons to Add Veeva Systems Stock to Your Portfolio for Now",
      "id": 136320683,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "VEEV's strong first quarter, product innovations and strategic deals drive growth prospects despite rising costs.",
      "url": "https://finnhub.io/api/news?id=4513415e80b937a674ba533c72eabee702be6345ccfc1b95da6844046787c23c"
    }
  },
  {
    "ts": null,
    "headline": "CAH Q4 Earnings Beat Estimates, '26 EPS View Up, Stock Falls",
    "summary": "Cardinal Health's fourth-quarter fiscal 2025 results benefit from solid Medical and Other segments' revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.",
    "url": "https://finnhub.io/api/news?id=044386165fd55d02dbada5f107f17b214d31055e917f26c91a2ba27c6c948250",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755009420,
      "headline": "CAH Q4 Earnings Beat Estimates, '26 EPS View Up, Stock Falls",
      "id": 136320684,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Cardinal Health's fourth-quarter fiscal 2025 results benefit from solid Medical and Other segments' revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.",
      "url": "https://finnhub.io/api/news?id=044386165fd55d02dbada5f107f17b214d31055e917f26c91a2ba27c6c948250"
    }
  },
  {
    "ts": null,
    "headline": "EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up",
    "summary": "Exact Sciences tops on Q2 earnings and revenue estimates and raises the 2025 outlook, but shares slide 8% after results.",
    "url": "https://finnhub.io/api/news?id=f75ad397bd85e3e1bf2d30604a7a57b980209d33fa537bf130b4094d1a053265",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755001620,
      "headline": "EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up",
      "id": 136317370,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Exact Sciences tops on Q2 earnings and revenue estimates and raises the 2025 outlook, but shares slide 8% after results.",
      "url": "https://finnhub.io/api/news?id=f75ad397bd85e3e1bf2d30604a7a57b980209d33fa537bf130b4094d1a053265"
    }
  },
  {
    "ts": null,
    "headline": "Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise",
    "summary": "PODD posts strong Q2 earnings and revenues and lifts its 2025 outlook, marking a decade of 20%+ constant-currency growth.",
    "url": "https://finnhub.io/api/news?id=fc1d97a637e9cdd70137a954d04aaafba3854a2d3939acef7595c2c97292cd7a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755001500,
      "headline": "Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise",
      "id": 136320686,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "PODD posts strong Q2 earnings and revenues and lifts its 2025 outlook, marking a decade of 20%+ constant-currency growth.",
      "url": "https://finnhub.io/api/news?id=fc1d97a637e9cdd70137a954d04aaafba3854a2d3939acef7595c2c97292cd7a"
    }
  },
  {
    "ts": null,
    "headline": "J&J's MedTech Unit Sales Improve in Q2: Will the Upside Continue?",
    "summary": "Johnson & Johnson's Q2 MedTech sales beat estimates, fueled by cardiovascular gains, surgical vision growth and new product momentum.",
    "url": "https://finnhub.io/api/news?id=32ba43e416a62973a55c0e38baf415158e7527a24a19773743c353f9c87bc87c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755000840,
      "headline": "J&J's MedTech Unit Sales Improve in Q2: Will the Upside Continue?",
      "id": 136320474,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Johnson & Johnson's Q2 MedTech sales beat estimates, fueled by cardiovascular gains, surgical vision growth and new product momentum.",
      "url": "https://finnhub.io/api/news?id=32ba43e416a62973a55c0e38baf415158e7527a24a19773743c353f9c87bc87c"
    }
  },
  {
    "ts": null,
    "headline": "US Durable Medical Equipment Market Forecast and Competitive Landscape Report 2025-2033 | Invacare, NOVA, Inogen, Thermo Fisher Scientific, Abbott, Medtronic, Baxter, B. Braun, Boston Scientific, BD",
    "summary": "The United States Durable Medical Equipment Market is projected to grow at a CAGR of 5.03% from 2025 to 2033, reaching $97.10 billion by 2033, driven by rising chronic diseases, an aging population, and increased home healthcare demand. Key segments include personal mobility devices and monitoring and therapeutic equipment, with top players like Invacare, Abbott, and Medtronic leading innovations. California and New York are vibrant markets due to their demographics and healthcare infrastructure",
    "url": "https://finnhub.io/api/news?id=1140dfc5dd7cec2d734c3a79338c0bdded44a93ccec66bce7f41a4885c74bde3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754988120,
      "headline": "US Durable Medical Equipment Market Forecast and Competitive Landscape Report 2025-2033 | Invacare, NOVA, Inogen, Thermo Fisher Scientific, Abbott, Medtronic, Baxter, B. Braun, Boston Scientific, BD",
      "id": 136316075,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "The United States Durable Medical Equipment Market is projected to grow at a CAGR of 5.03% from 2025 to 2033, reaching $97.10 billion by 2033, driven by rising chronic diseases, an aging population, and increased home healthcare demand. Key segments include personal mobility devices and monitoring and therapeutic equipment, with top players like Invacare, Abbott, and Medtronic leading innovations. California and New York are vibrant markets due to their demographics and healthcare infrastructure",
      "url": "https://finnhub.io/api/news?id=1140dfc5dd7cec2d734c3a79338c0bdded44a93ccec66bce7f41a4885c74bde3"
    }
  }
]